CVnCoV SARS-CoV-2 Vaccine Description
CureVac's CVnCoV is an mRNA vaccine candidate that utilizes nucleotides without chemical modifications in the mRNA. The vaccine candidate is designed to provide a strong and balanced activation of the immune system.
The mRNA encodes the full-length spike protein of SARS-CoV-2 coronavirus and is formulated with lipid nanoparticles.
CureVac’s RNAoptimizer platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization, and mRNA delivery.
The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases.
The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.
Each CureVac product can be thought of as a tailored molecular creation in which we customize the 5’ and 3’ untranslated regions and the open reading frame to ensure translation of the mRNA sequence produces the ideal levels of protein creation in the body.
All the different parts of a CureVac-customized mRNA molecule create a packaged product specially optimized for different indications.
CureVac AG is a clinical-stage biotechnology company located in Tübingen, Germany.
CVnCoV SARS-CoV-2 Vaccine Indication
CVnCoV is indicated to prevent infection from the SARS-CoV-2 coronavirus which causes COVID-19 disease.
CVnCoV SARS-CoV-2 Vaccine Dosage
A dose range of 2 µg to 8 µg will be tested to determine the optimal dose as well as to evaluate the safety and immune profile of the vaccine in humans.
CVnCoV SARS-CoV-2 Vaccine News
July 2, 2020 - Elon Musk Tweeted Tesla Inc. is building mobile molecule printers to help make the potential COVID-19 vaccine named CVnCoV being developed by CureVac in Germany.
June 17, 2020 - CureVac to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate.
June 15, 2020 - The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp announced that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.
May 14, 2020 - CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a fast induction of a balanced immune response with high levels of virus-neutralizing titers (VNTs) and T-cell responses. VNTs are a major criterion supporting that the vaccine candidate has the potential to induce a strong immunologic response to neutralize SARS-CoV-2.
CVnCoV SARS-CoV-2 Vaccine Clinical Trials
Clinical Trial NCT04449276: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults
- This Phase 1 study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.